390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial

Erika Hamilton, Hyo S. Han, Anne F. Schott, Antoinette R. Tan, Rita Nanda, Dejan Juric, N. Hunter, Pamela N. Münster, Bruno Fang, G. Zahrah, J. Ranciato, Richard Gedrich, Eric Zhi, Y. Zhang, Weiwei Tan, C. Mather, Jessica M. Perkins, Sibyl Anderson, Sara A. Hurvitz